Lifecore Biomedical (NASDAQ:LFCR) Upgraded to Hold at Wall Street Zen

Key Points

• Lifecore Biomedical's stock rating was upgraded from "sell" to "hold" by analysts at Wall Street Zen.
• Despite recent upgrades, Lifecore Biomedical reported a loss of ($0.10) earnings per share, missing the consensus estimate of ($0.09).
• Major shareholder Aron R. English sold over 1.1 million shares of the company, decreasing their ownership by 73.32%.

Lifecore Biomedical (NASDAQ:LFCR - Get Free Report) was upgraded by Wall Street Zen from a "sell" rating to a "hold" rating in a research note issued to investors on Saturday.

Separately, William Blair assumed coverage on shares of Lifecore Biomedical in a research report on Wednesday, May 21st. They set an "outperform" rating for the company. Two equities research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company. According to MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average target price of $8.00.

Lifecore Biomedical Trading Down 0.8%

Shares of LFCR stock traded down $0.0550 during trading hours on Friday, hitting $7.1950. 18,492 shares of the company's stock traded hands, compared to its average volume of 216,943. The stock's 50 day simple moving average is $7.55 and its 200 day simple moving average is $6.78. The stock has a market cap of $269.16 million, a PE ratio of -5.48 and a beta of 0.65. Lifecore Biomedical has a 12 month low of $3.68 and a 12 month high of $8.85. The company has a quick ratio of 1.77, a current ratio of 2.84 and a debt-to-equity ratio of 113.76.

Lifecore Biomedical (NASDAQ:LFCR - Get Free Report) last released its quarterly earnings results on Thursday, August 7th. The company reported ($0.10) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.09) by ($0.01). The business had revenue of $36.44 million for the quarter, compared to the consensus estimate of $35.36 million. Lifecore Biomedical had a negative net margin of 31.70% and a negative return on equity of 846.51%. Lifecore Biomedical has set its FY 2026 guidance at EPS. On average, sell-side analysts anticipate that Lifecore Biomedical will post -0.91 EPS for the current year.

Insider Buying and Selling

In other Lifecore Biomedical news, major shareholder Aron R. English sold 150,419 shares of the firm's stock in a transaction on Wednesday, May 28th. The shares were sold at an average price of $7.12, for a total value of $1,070,983.28. Following the completion of the sale, the insider directly owned 264,180 shares in the company, valued at approximately $1,880,961.60. This trade represents a 36.28% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Insiders have sold 1,386,060 shares of company stock valued at $9,126,684 in the last ninety days. Company insiders own 32.20% of the company's stock.

Institutional Investors Weigh In On Lifecore Biomedical

A number of large investors have recently bought and sold shares of LFCR. State of Wyoming acquired a new position in shares of Lifecore Biomedical during the second quarter worth approximately $69,000. Tactive Advisors LLC acquired a new position in shares of Lifecore Biomedical during the second quarter worth approximately $126,000. Grizzlyrock Capital LLC acquired a new position in shares of Lifecore Biomedical during the second quarter worth approximately $5,964,000. The Manufacturers Life Insurance Company acquired a new position in shares of Lifecore Biomedical during the second quarter worth approximately $88,000. Finally, Pale Fire Capital SE acquired a new position in shares of Lifecore Biomedical during the second quarter valued at about $249,000. 83.36% of the stock is currently owned by institutional investors and hedge funds.

About Lifecore Biomedical

Lifecore Biomedical, Inc, together with its subsidiaries, operates as an integrated contract development and manufacturing organization in the United States and internationally. The company engages in the manufacturing of pharmaceutical-grade sodium hyaluronate (HA) in bulk form, as well as formulated and filled syringes and vials for injectable products used in treating a range of medical conditions and procedures.